抗体药物研发商Argenx获得欧盟委员会批准VYVGART®皮下注射与ENHANZE®联合治疗慢性炎症性脱髓鞘性多发性神经病Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

动脉网
Yesterday

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:/PRNewswire/ -- Halozyme Therapeutics, Inc.(纳斯达克:) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10